ROCO
8432
Market cap64mUSD
Oct 08, Last price
53.20TWD
1D
-1.12%
1Q
4.93%
Jan 2017
-26.21%
IPO
-33.16%
Name
TSH Biopharm Corporation Ltd
Chart & performance
P/E
14.67
P/S
1.53
EPS
3.63
Div yield, %
3.98%
Shrs. gr., 5y
6.13%
Rev. gr., 5y
24.44%
Revenues
1.34b
+19.79%
Net income
139m
+23.14%
CFO
155m
-15.76%
Dividend
Jun 12, 20262.61 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TSH Biopharm Corporation Limited, a subsidiary of TTY Biopharm Company Limited, specializes in the development and commercialization of pharmaceutical products. Established in 1999 with its headquarters in Taipei, Taiwan, the company's market reach extends across Taiwan and other Asian territories. Its product portfolio encompasses a variety of therapeutic solutions, including treatments for cardiovascular, central nervous system, and gastrointestinal conditions, among others.
Key people
Rongliang Gao
Chief Financial Officer · since 2024
Sze-Yuan Yang
General Manager · since 2024
Shu-ping Huang
Head of Finance · since 2023
Director · since 2020
Director · since 2019
Chairman of the Board · since 2020
Yongliang Wu
Director · since 2023
Independent Director · since 2018
Yaobin Huang
Independent Director · since 2022
Independent Director · since 2024
Independent Director · since 2024
Deyu Zhou
Independent Director · since 2023
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||